AstraZeneca Plc - Company Profile
Powered by
All the data and insights you need on AstraZeneca Plc in one report.
- Save hours of research time and resources with
our up-to-date AstraZeneca Plc Strategy Report
- Understand AstraZeneca Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreAstraZeneca Plc Catalyst Calendar
Proactively evaluate AstraZeneca Plc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of AstraZeneca Plc Catalyst Calendar data
Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
---|---|---|---|---|---|---|---|
31 Aug 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
30 Aug 2019 | Phase I/II Trial Initiation | AstraZeneca Plc | AZN | acalabrutinib maleate | Oncology | Chronic Lymphocytic Leukemia (CLL); Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Non-Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia (CLL); Relapsed Chronic Lymphocytic Leukemia (CLL); Unspecified B-Cell Lymphomas | Clinical Trial Registry |
27 Aug 2019 | Phase I Trial Completion | MedImmune LLC (Inactive) | - | cotadutide | Metabolic Disorders | Obesity | Clinical Trial Registry |
27 Aug 2019 | Phase II/III Trial Completion | AstraZeneca Plc; Merck & Co Inc; Myriad Genetics Inc; PPD Inc | AZN; MRK; MYGN | cediranib maleate; olaparib | Oncology | Epithelial Ovarian Cancer; Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer | Company Reports |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer